ReviewFrontiers in cell and developmental biology2023
Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer.
Review in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis.Frontiers in oncology · 2024Pooled it
- Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers.Molecular therapy. Oncology · 2026Review
- Targeting Triple-Negative Breast Cancer: A Special Focus on Phototherapy and Nanomaterials.Molecules (Basel, Switzerland) · 2026Review
- Macrophages expressing chimeric cytokine receptors have an inflammatory phenotype and antitumoral activity upon IL-10 or TGFβ stimulation.Journal for immunotherapy of cancer · 2025Article
- Deep learning reconstruction for accelerating synthetic magnetic resonance imaging of the breast: a comparative analysis of accelerated and standard protocols.Quantitative imaging in medicine and surgery · 2025Article
- Colorectal Cancer; Novel Approaches in Chimeric Antigen Receptors (CAR) -T cell.International journal of molecular and cellular medicine · 2025Review
- Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment.International journal of molecular and cellular medicine · 2025Review
- Repurposing anti-osteoporosis drugs for autoimmune diseases: A two-sample Mendelian randomization study.Heliyon · 2024Article
- Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is highly aggressive and does not express estrogen receptor (ER), progesterone (PR), or human epidermal growth factor receptor 2 (HER2). It has a poor prognosis, and traditional endocrine and anti-HER2 targeted therapies have low efficacy against it. In contrast, surgery, radiotherapy, and/or systemic chemotherapy are relatively effective at controlling TNBC. The resistance of TNBC to currently available clinical therapies has had a significantly negative impact on its treatment outcomes. Hence, new therapeutic options are urgently required. Chimeric antigen receptor T cell (CAR-T) therapy is a type of immunotherapy that integrates the antigen specificity of antibodies and the tumor-killing effect of T cells. CAR-T therapy has demonstrated excellent clinical efficacy against hematological cancers. However, its efficacy against solid tumors such as TNBC is inadequate. The present review aimed to investigate various aspects of CAR-T administration as TNBC therapy. We summarized the potential therapeutic targets of CAR-T that were identified in preclinical studies and clinical trials on TNBC. We addressed the limitations of using CAR-T in the treatment of TNBC in particular and solid tumors in general and explored key strategies to overcome these impediments. Finally, we comprehensively examined the advancement of CAR-T immunotherapy as well as countermeasures that could improve its efficacy as a TNBC treatment and the prognosis of patients with this type of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.